- Home
- PAX vs SDGR Comparison
PAX vs SDGR Comparison
Compare PAX & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAX
- SDGR
- Stock Information
- Founded
- PAX 1988
- SDGR 1990
- Country
- PAX Cayman Islands
- SDGR United States
- Employees
- PAX N/A
- SDGR N/A
- Industry
- PAX Investment Managers
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- PAX Finance
- SDGR Health Care
- Exchange
- PAX Nasdaq
- SDGR Nasdaq
- Market Cap
- PAX 1.8B
- SDGR 1.8B
- IPO Year
- PAX 2021
- SDGR 2020
- Fundamental
- Price
- PAX $11.97
- SDGR $22.64
- Analyst Decision
- PAX Strong Buy
- SDGR Buy
- Analyst Count
- PAX 1
- SDGR 9
- Target Price
- PAX $14.00
- SDGR $32.11
- AVG Volume (30 Days)
- PAX 546.8K
- SDGR 1.1M
- Earning Date
- PAX 02-12-2025
- SDGR 02-26-2025
- Dividend Yield
- PAX 5.01%
- SDGR N/A
- EPS Growth
- PAX N/A
- SDGR N/A
- EPS
- PAX 0.48
- SDGR N/A
- Revenue
- PAX $374,200,000.00
- SDGR $193,348,000.00
- Revenue This Year
- PAX $6.33
- SDGR N/A
- Revenue Next Year
- PAX $4.55
- SDGR $31.43
- P/E Ratio
- PAX $25.05
- SDGR N/A
- Revenue Growth
- PAX 14.22
- SDGR N/A
- 52 Week Low
- PAX $10.63
- SDGR $16.67
- 52 Week High
- PAX $15.23
- SDGR $33.63
- Technical
- Relative Strength Index (RSI)
- PAX 48.11
- SDGR 43.67
- Support Level
- PAX $11.69
- SDGR $23.14
- Resistance Level
- PAX $12.83
- SDGR $28.47
- Average True Range (ATR)
- PAX 0.32
- SDGR 1.60
- MACD
- PAX 0.01
- SDGR -0.34
- Stochastic Oscillator
- PAX 34.60
- SDGR 9.19
About PAX Patria Investments Limited
Patria Investments Ltd is a private markets investment firm. It seeks to provide global and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.